RECRUITING

iExposure Intervention for Social Anxiety

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Social anxiety (SA) is a highly prevalent mental health concern, thought to disproportionately affect youth with recent international estimates of more than 30% of individuals reporting clinically elevated symptoms. Despite the prevalence of SA, as few as one in five individuals receive care, due to limited access to evidence-based treatments. Additionally there has been a notable increase in social anxiety since the start of the COVID-19 pandemic. This proposal will use iExposure to develop a personalized mechanism-focused approach to optimizing treatment response for individuals with social anxiety by testing standard iExposure against two augmentations that incorporate distinct attention mechanisms (attention guidance and attention control).

Official Title

Testing the Role of Attentional and Audio Vocal Mechanisms in a New Internet- Based Intervention for Social Anxiety: iExposure

Quick Facts

Study Start:2024-07-01
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06409247

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 or older
  2. * Fluent in English
  3. * Leibowitz Social Anxiety Scale \> 47 and endorses both social anxiety items on the Web Screening Questionnaire for Common Mental Disorders
  1. * Currently receiving CBT for Social Anxiety Disorder
  2. * Significant visual impairment precluding engagement in the simulated teleconferencing interactions
  3. * Unstable dose of psychotropic medications within 6 weeks prior to baseline assessment
  4. * Current alcohol or substance use disorder
  5. * Current or past bipolar disorder or psychosis

Contacts and Locations

Study Contact

Mikael Rubin, PhD
CONTACT
650-433-3805
mrubin@paloaltou.edu

Study Locations (Sites)

Palo Alto University
Palo Alto, California, 94304
United States

Collaborators and Investigators

Sponsor: Palo Alto University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-01
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2024-07-01
Study Completion Date2026-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Social Anxiety